profit from every $100 of sales.
$0$100
Palisade Bio
$1.12-1.75% today
-40.1% in 1 year
1-year low $1.121-year high $2.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Palisade Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$16.8 million of profit last year.
SalesProfit
Palisade Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Palisade Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Palisade Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -15 | -13 | -15 | -18 | |
| -14 | -12 | -14 | -17 | |
| -14 | -12 | -14 | -17 | |
| -247.95 | -27.01 | -10.19 | -0.30 | |
| – | – | – | – | |
| – | -5,138.0% | – | – | |
| – | -4,920.0% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 16 | 14 | 11 | 134 |
| Cash | 12 | 12 | 10 | 133 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 3 | 3 | 3 | 5 |
| 12 | 11 | 7 | 129 | |
| 0 | 0 | 1 | 56 | |
| -87.4% | -83.1% | -148.8% | -10.2% | |
| -114.3% | -108.7% | -192.7% | -13.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -11 | -12 | -11 | |
| 0 | 0 | – | – | |
| -13 | -11 | -12 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 4 |
Valuation
- –
- –
- –
- 3.1×
- 804.1×
- –
- –
- -5.5%
- -6.1%
- 0.0%
Profitability
- 0.0%
- -5,138.0%
- -4,920.0%
- 0.0%
- -20.7%
- -153.9%
- -36.8%
- -18.1%
- -20.7%
- –
Growth
- –
- –
- +11.0%
- –
- +718.3%
Financial health
- -1.0×
- 0.00
- 0.0%
- -3,311.8×
- 23.71
- 23.71
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 952
Bottom 17%of 987
What analysts expect
- Average price target
- $1.50
- Range
- $1.50 – $1.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.05 | -0.04 | −25.0% |
| Mar 23, 2026 | -0.04 | -0.02 | −100.0% |
| Nov 10, 2025 | -0.38 | -0.32 | −18.8% |
| Aug 11, 2025 | -0.58 | -0.48 | −20.8% |
| May 12, 2025 | -0.47 | -0.84 | +44.0% |
| Mar 24, 2025 | -0.69 | -1.99 | +65.3% |
| Nov 12, 2024 | -2.32 | -3.35 | +30.7% |
| Aug 12, 2024 | -3.32 | -2.93 | −13.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
40No pass
Philip Fisher
37No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
25No pass
Questions about Palisade Bio
Is Palisade Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Palisade Bio AI analysis
What does Palisade Bio do?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. It is in Biotechnology.
Does Palisade Bio pay a dividend?
No. Palisade Bio does not pay a dividend at the moment.
Is Palisade Bio stock halal?
No. Palisade Bio does not pass our halal screen: its cash and confirmed interest-bearing investments are 66% of its market value, at or above the 33% limit. How we check
How has Palisade Bio stock done over the past year?
Down 40.1% over the past twelve months, to $1.12. It traded between $1.12 and $2.80 and is 60.0% below its high.
Who are Palisade Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Palisade Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.